Regeneron Pharmaceuticals (NASDAQ:REGN) Coverage Initiated at Wolfe Research

Analysts at Wolfe Research began coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) in a research report issued to clients and investors on Friday, Marketbeat Ratings reports. The firm set an "outperform" rating and a $1,150.00 price target on the biopharmaceutical company's stock. Wolfe Research's price target indicates a potential upside of 51.95% from the stock's current price.

A number of other equities analysts also recently issued reports on the stock. Barclays cut their price objective on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an "overweight" rating on the stock in a report on Friday, November 1st. Morgan Stanley cut their price objective on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating for the company in a report on Friday, November 1st. StockNews.com lowered Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Monday, November 4th. Cantor Fitzgerald restated a "neutral" rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Finally, BMO Capital Markets dropped their price objective on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an "outperform" rating on the stock in a research report on Friday, November 1st. One analyst has rated the stock with a sell rating, four have assigned a hold rating and nineteen have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $1,099.55.

Regeneron Pharmaceuticals Price Performance

Shares of REGN traded down $25.70 during mid-day trading on Friday, reaching $756.81. The company had a trading volume of 1,371,787 shares, compared to its average volume of 530,445. The company's 50 day simple moving average is $992.70 and its 200 day simple moving average is $1,033.92. Regeneron Pharmaceuticals has a 1-year low of $753.69 and a 1-year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The company has a market capitalization of $83.17 billion, a price-to-earnings ratio of 18.93, a P/E/G ratio of 3.04 and a beta of 0.15.

Insider Buying and Selling

In other news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares of the company's stock, valued at $18,447,575.65. The trade was a 27.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 7.48% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of REGN. State Street Corp lifted its position in Regeneron Pharmaceuticals by 1.3% in the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company's stock worth $5,153,603,000 after purchasing an additional 61,277 shares during the period. Stevens Capital Management LP acquired a new position in shares of Regeneron Pharmaceuticals in the third quarter worth $475,000. Stifel Financial Corp increased its stake in shares of Regeneron Pharmaceuticals by 7.3% in the third quarter. Stifel Financial Corp now owns 48,245 shares of the biopharmaceutical company's stock worth $50,717,000 after acquiring an additional 3,271 shares during the last quarter. Quantinno Capital Management LP lifted its stake in shares of Regeneron Pharmaceuticals by 59.9% in the third quarter. Quantinno Capital Management LP now owns 7,473 shares of the biopharmaceutical company's stock valued at $7,856,000 after buying an additional 2,798 shares during the period. Finally, Royal London Asset Management Ltd. lifted its stake in shares of Regeneron Pharmaceuticals by 2.7% in the third quarter. Royal London Asset Management Ltd. now owns 43,675 shares of the biopharmaceutical company's stock valued at $45,913,000 after buying an additional 1,152 shares during the period. Institutional investors and hedge funds own 83.31% of the company's stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.